Ropero TR, Proveyer DS, Fernández SE, Orellana AMR, Lugioyo LMI, Ávila PJ

Language: Spanish
References: 8
Page: 26-30
PDF size: 691.55 Kb.

ABSTRACT

Background. During pharmaceutical validation requirements carboplatin treatment regimens in patients with lung cancer, deficiencies related to the individual adjustment of the dose was found, classifying drug prescriptions in 26 potential mistakes A type. These results led to the implementation of measures; but in subsequent validations the problem persisted so it is important to know the causes of this failure. Methods. A questionnaire to residents in the specialty of Oncology consisting of two questions for exploring the aim of identifying the knowledge they have on area under curve (AUC) and dose calculation carboplatin. Results. 28 residents completed the questionnaire; 17 with over 4 years of experience, 57.4% of the total has more than two years in residence, 57% correctly answered the first question, 43% the second and only 21, 4% answered correctly both. Conclusions. The information to residents on the calculation of the dose of carboplatin is low, which could have an important impact on the generation of prescribing errors; an educational intervention is required to improve it.

REFERENCES

1. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22.

2. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41

3. Notari, R. Biopharmaceutical and clinical pharmacokinetics: an introduction. Ed. Marcel D Ekker Inc., N. Y. 3ra Ed., pp. 26-33, 1985.

4. Calvert AH, Newell DR, Gumbell LA. O´Reilly S, Burnell M, Boxall FR et al. Carboplatin dosage Prospective evaluation of simple formula based on renal function. J Clin Oncol 1989; 7:1748-56

5. Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working party. Eur J Cancer 1999; 35: 1314-9.

6. Martindale: the complete drug reference. 35 ed. London: Pharmaceutical Press; 2006

7. Garcia M, Castellanos Y, Diez FR, Martínez J M, Iglesias A M, Hernández B. Análisis retrospectivo de la dosificación de carboplatino y relación con su toxicidad en pacientes oncológicos. Farm Hosp 31(4), pp. 218-222, 2007

8. Arbesú MA, Proveyer S, Ropero R, Fente BA, Cruzata A. Detección de errores potenciales de prescripción de carboplatino mediante validación farmacéutica. Revista Cubana de Farmacia. 2011; 45 (2).